
Arvinas has managed to secure another big pharma collaboration, after it announced that Pfizer had signed a research and licensing …

Allergan was never far away from the headlines in 2017, particularly when it came to its second highest selling product, …

Syntimmune has revealed that it has brought in a new CEO to begin the new year, with the appointment of …

Spark Therapeutics knew that it had to think very carefully about where it pitched its price for its inarguably ground-breaking …

Johnson & Johnson has revealed Phase 2 data for its treatment for depression, esketamine, and the results are positive. The …

Novartis has received a major boost in its efforts to broaden use of its CDK4/6 inhibitor, by receiving a breakthrough …

Mallinckrodt has endured a tough 2017, with its share price falling by half over the course of the year. This …

There was ample warning that the NHS looked set to face another difficult winter season, the predictions now look to …

A group of researchers at Lancaster University have identified a drug currently used to treat type 2 diabetes that has …

GW Pharmaceuticals had a busy festive period, after it announced that it had submitted to both the EU and the …

Back in August of 2017, NICE rejected Pfizer’s Besponsa on cost-effectiveness grounds and the pharma giant was not best pleased. …

Continuing its recent trend to promote innovative new technologies, the FDA has announced that it has approved a medical device …

Since Mylan and Biocon managed to gain US FDA approval for its Herceptin (Trastuzumab) biosimilar, it has forged ahead in …

Valeant Pharmaceuticals will be hoping it can begin 2018 as a fresh start, after a turbulent few years, to say …

In a landmark ruling, a Californian court has found that a brand name manufacturer of a drug could be held …